You are here

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Little Rock, Arkansas, 72211 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myelogenous Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with CD33+ AML who have experienced relapse after autologous or allogeneic
HSCT. Flow cytometry, performed at the study site, must demonstrate that the patient
has AML that is CD33 positive, based on local laboratory criteria (Patients with
history of MDS pretransplant will be eligible if their proportion of myeloblasts by
marrow aspirate exceeds 5% at time of evaluation for Gemtuzumab Ozogamicin treatment)

- The patient must be greater than or equal to 60 days post-HCST

- Patients of all ages may be entered in this study

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Peripheral white blood count (WBC) greater than or equal to 30,000/uL at the time of
initial Gemtuzumab Ozogamicin administration. (In order to reduce the peripheral blood
count, patients may be treated with Hydroxyurea. Hydroxyurea must be discontinued 24
hours prior to Gemtuzumab Ozogamicin administration.)

- Known active central nervous system (CNS) or testicular leukemia at time of study
entry.

- Prior therapy with anti-CD33 antibodies.

NCT00044733
Pfizer
Completed
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now